

DATA SHEET
Hsa-miR-10bProbe

Catalog No	Description
HM010B-100	One vial of 0.650 ml of probe in hybridization buffer

Analyte Specific Reagent. Analytical and performance characteristics are not established.

Doc. No. 932-HM010B-100 Rev : E
Date of release: 31-Jul-2024

Description

The Hsa-miR-10b probe has been designed from mature human miR-10b sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

Specifications

The Hsa-miR-10b identifies mature miR-10b sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

Storage and Handling

Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

Precautions:

For professional use. The probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

Quality Control

Each lot of this micro RNA probe is tested by *In Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

References

1. Lorio MV and Croce CM. (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med* 4, 143–159.
2. Chen PS, Su JL, and Hung MC. (2012). Dysregulation of Micro RNAs in cancer. *Journal of Biomedical Science*, 19:90.
3. Nuovo GJ. (2008). In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. *Methods* 44,39–46.
4. Song R, Ro S, Yan W. (2010). *In situ* hybridization detection of microRNAs. *Methods Mol Biol.* 629, 287-94.
5. Ma L, Teruya-Feldstein J, Weinberg RA. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature*.449,682-8.
6. Mestdagh P., Mestdagh P, LefeverS,PattynF,Ridzon D, Fredlund E, Fieuw A, Ongenaert M, Vermeulen J, Paepe AD, Wong L, Speleman F, Chen C, Vandesompele J. (2011).The microRNA body map: dissecting microRNA function through integrative genomics. *Nucleic Acids Res.*39,20 e136.

7. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM, MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. **JAMA**2007; 297:1901-1908.
8. Ciafre SA, Galardi S, Mangiola, A, Ferracin, M, Liu, CG, Sabatiano G, Negrini M, Maira G, Croce, CM, Farace MG.(2005). Extensive modulation of a set of microRNAs in primary glioblastoma. *BiochemBiophys Res Commun.* 2005; 334:1351-1358

BioGenex Quality Control Testing Conditions

Parameter	Conditions used
Control Tissue	PROSTATE Ca., SMALL CELL LUNG Ca.(FB-HM010B)
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues